GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced today a significant step forward in the development of a vaccine candidate for protection against Lassa hemorrhagic...Read more
GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced today that it is scheduling corporate partnering meetings during the BIO International Convention, to be held in San...Read more
GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing preventative and therapeutic human vaccines against infectious diseases and cancer. The Company’s unique and patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated person mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector. GeoVax is currently focused on developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), and malaria. The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). GeoVax believes its technology and development expertise is complementary to a range of other human diseases for which there is an unmet medical need, and accordingly, has plans to expand its pipeline.
* The Corporate Snapshot was last updated on June 19, 2017.